Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy and safety of the combination regimen of
bortezomib-bendamustine-dexamethasone in patients with relapsed or refractory multiple
myeloma